Investors with a lot of money to spend have taken a bearish stance on Gilead Sciences GILD. And retail traders should know.

Investors in Gilead Sciences Inc (Symbol: GILD) saw new options become available today, for the May 9th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GILD ...

Gilead Sciences (NASDAQ:GILD – Get Free Report) had its price target lifted by stock analysts at JPMorgan Chase & Co. from ...

Citigroup said it’s “very bullish” on Gilead’s HIV franchise, arguing it’s the drugmaker’s biggest value driver as the company’s new ...

Below is Validea's guru fundamental report for GILEAD SCIENCES INC (GILD). Of the 22 guru strategies we follow, GILD rates highest using our Twin Momentum Investor model based on the published ...

In the latest trading session, Gilead Sciences (GILD) closed at $106.67, marking a -0.38% move from the previous day. The stock fell short of the S&P 500, which registered a gain of 1.77% for the day.

Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Gilead Sciences ...

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

Nuffin' says lovin' like a Higbee's Muffin and this week, we set the Time Machine for a department store odyssey that ends ...

Gilead Sciences (NASDAQ:GILD) had reported double-digit growth in two areas of its commercial products portfolio when it released its Q4 and Full-year 2024 earnings back on February 11th of 2025.

FOSTER CITY, Calif., March 12, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of late-breaking data and multiple oral presentations from its innovative HIV treatment ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Has Gilead Sciences (GILD) been one of those stocks this year?